Caring Brands (CABR) Registration Filing summary

Company overview and business model

• Operates as a wellness consumer products company offering OTC and cosmetic products for skin, hair, and wellness, with a focus on clinically validated, patent-protected formulations.

• Product portfolio includes Photocil (for vitiligo and psoriasis), Hair Enzyme Booster (JW-700), CB-101 (eczema), and No Stingz (sunscreen/jellyfish protection).

• Products are sold in India and the U.S., with expansion plans for other international markets and a direct-to-consumer e-commerce strategy.

• Business model leverages licensing agreements, third-party manufacturing, and strategic partnerships for distribution.

Financial performance and metrics

• Nominal revenues reported: $3,056 for the six months ended June 30, 2025, and $465 for the period April 24 to December 31, 2024.

• Net losses: $(1,199,353) for the six months ended June 30, 2025, and $(862,791) for the period April 24 to December 31, 2024.

• Cash and cash equivalents as of June 30, 2025: $73,893; as of December 31, 2024: $468,998.

• Private placement in 2024 raised $2,110,000; net proceeds used for working capital and capital expenditures.

• Pro forma net tangible book value per share after offering: $0.22; immediate dilution to new investors: $3.77 per share.

Use of proceeds and capital allocation

• Net proceeds of ~$3,200,000 from the IPO to fund product development, manufacturing, marketing, clinical testing, regulatory filings, and general working capital.

• Allocation includes $700,000 for Hair Enzyme Booster manufacturing and marketing, $505,000 for Photocil scale-up and launch, $385,000 for CB-101 development, and $310,000 for No Stingz reformulation and production.

• Proceeds expected to fund operations for approximately 12 months.